-
ISPOR Europe 2024-Digital Conference Pass
Join global healthcare leaders as they convene at ISPOR Europe 2024, the leading global conference for Health Economics and Outcomes Research (HEOR) in-person and virtually for discussion and dissemination of the latest trends in healthcare. This must-attend event provides you with dedicated opportunities to network in-person and virtually with your peers, HEOR experts, and thought leaders and to discuss with a global audience how we establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
-
December 3: Primer on a 6-Step Approach to Budget Impact Analysis- Virtual
-
ISPOR Real-World Evidence Summit 2024
, BARCELONA | SPAIN
This summit will cover latest developments in use of real world evidence across regulatory-HTA-payer decision-making continuum with focus on methods, data transportability, and infrastructure. Major methods topics to be covered include causal inference and external control arms for comparative effectiveness analyses, the hierarchy of RWE studies, and the role of patient registries. Use of RWE in Joint Clinical Assessment of the EU HTA regulation will be explored, also with insights from the cross-border collaborations on pricing and reimbursement in the EU countries. Finally, feasibility of HTA reassessment post market entry will be considered, drawing from lessons learned from US Medicare Drug Price Negotiation.
-
November 17: Applied Cost-Effectiveness Modeling with R - In Person at ISPOR Europe 2024
-
November 17: Advanced Patient-Reported Outcomes - In Person at ISPOR Europe 2024
-
November 17: AI-Powered HEOR: Advancing Insights and Decisions with Large Language Models - In Person at ISPOR Europe 2024
-
November 17: Going Beyond the Standard: Exploring Advanced Survival Modeling Techniques - In Person at ISPOR Europe 2024
-
November 17: Health Technology Assessment for Rare Diseases - In Person at ISPOR Europe 2024
-
November 17: Introduction to Machine Learning Methods - In Person at ISPOR Europe 2024
-
November 17: Valuation of Innovative Drugs - In Person at ISPOR Europe 2024
-
November 17: Core Concepts and Approaches to Early-Stage Health Technology Assessment - In Person at ISPOR Europe 2024
-
November 17: Reimbursement Systems for Pharmaceuticals in Europe - In Person at ISPOR Europe 2024
-
November 17: Developing Decision-Grade Real-World Evidence - In Person at ISPOR Europe 2024
-
November 17: Introduction to Applied Generative AI for HEOR - In Person at ISPOR Europe 2024
-
November 17: Real-World Evidence in External Control Arms: Driving Innovation in Drug Development - In Person at ISPOR Europe 2024
-
November 17: Introduction to Health Economics and Outcomes Research - In Person at ISPOR Europe 2024
-
November 17: Causal Inference and Causal Estimands From Target Trial Emulations Using Evidence from Real-World Observational Studies and Clinical Trials - In Person at ISPOR Europe 2024
-
November 17: Health Economic Modeling in R: A Hands-on Introduction - In Person at ISPOR Europe 2024
-
The Burden of Time: MS Treatment and Socio-Economic Impact Reduction
-
IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings